Lenacapavir represents a major advance in HIV prevention. As a capsid inhibitor, it interrupts multiple stages of the HIV lifecycle, making it distinct from other treatments. This long-acting injectable has shown remarkable efficacy in blocking HIV replication, making it a promising option for both prevention and treatment, particularly in heavily treatment-experienced adults with multi-drug-resistant HIV. The introduction of Lenacapavir is a game-changer, offering new hope to millions affected by HIV, especially in high-incidence, resource-limited countries. With Gilead’s recent voluntary licensing agreements, six generic manufacturers have been empowered to produce and supply Lenacapavir at low cost. This decision to roll out Lenacapavir through partnerships in 120 countries, including Botswana, South Africa, and Kenya, underscores Gilead’s commitment to global health equity. By offering the drug at no profit until generic manufacturers can meet demand, Gilead has set a new benchma...

On 30 August 2024 , the Botswana Community HIV Cure Research Academy was officially launched at the CEYOHO Centre in Tlokweng, marking a significant milestone in the fight against HIV. The launch of the Academy symbolises a new era where community-driven insights are integrated with scientific research to accelerate the global pursuit of an HIV cure. The event brought together a diverse group of stakeholders, including People Living with HIV (PLHIV), researchers, civil society organisations (CSOs), and other community representatives. Vision of the Academy The Academy’s vision is to become a pivotal platform that harmonises community-driven perspectives with scientific research, to accelerate progress towards finding a cure for HIV. It is designed to bridge the gap between PLHIV and researchers, ensuring that community members actively shape research efforts, study designs, and policy advocacy. The Academy aims to provide education and awareness on HIV cure science, advocate for ...